WCN26-3563 The Mineralocorticoid Receptor–TRPC5 pathway Drives Macrophage-Mediated Inflammation in Diabetic Kidney Disease

Read full text Summarise with VIRAT
Authors: Masafumi Wada, Hajime Nagasu, Hiroshi Kitao, Masanobu Takasu, Rie Tatsugawa, Tsukasa Iwakura, Yoshihisa Wada, Kengo Kidokoro, Naoki Kashihara
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Diabetic kidney disease (DKD) is a major cause of end-stage renal disease (ESRD). In DKD, a low-renin state typically limits aldosterone-dependent activation of the mineralocorticoid receptor (MR). However, under pathological conditions such as diabetes and obesity, aldosterone-independent MR activation occurs and contributes to renal injury progression. Recent clinical trials (FIGARO-DKD and FIDELIO-DKD) have demonstrated the renoprotective effects of finerenone, a non-steroidal MR antagonist, prompting its use in DKD treatment.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Hormonal Regulation and Hypertension Renin-Angiotensin System Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104605–104605
Publication date
25 March 2026
Language
EN